Eek D, Krohe M, Mazar I, Horsfield A, Pompilus F, Friebe R, et al. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence. 2016;10:1609–21.
Cinar D, Tas D. Cancer in the elderly. North Clin Istanb. 2015;2(1):73–80.
Bhatt VR. Cancer in older adults: understanding cause and effects of chemotherapy-related toxicities. Future Oncol. 2019;15(22):2557–60.
Dunn C, Wilson A, Sitas F. Older cancer patients in cancer clinical trials are underrepresented. Systematic literature review of almost 5000 meta- and pooled analyses of phase III randomized trials of survival from breast, prostate and lung cancer. Cancer Epidemiol. 2017;51:113–7.
François E, Azria D, Gourgou-Bourgade S, Jarlier M, Martel-Laffay I, Hennequin C, et al. Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy. Radiother Oncol. 2014;110(1):144–9.
Sastre J, Aranda E, Massutí B, Tabernero J, Chaves M, Abad A, et al. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. Crit Rev Oncol Hematol. 2009;70(2):134–44.
Leicher LW, de Graaf JC, Coers W, Tascilar M, de Groot JWB. Tolerability of Capecitabine Monotherapy in Metastatic Colorectal Cancer: A Real-World Study. Drugs R D. 2017;17(1):117–24.
Comella P, Natale D, Farris A, Gambardella A, Maiorino L, Massidda B, et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer. 2005;104(2):282–9.
Mason M, Harris MR, Greer JA, Jiang Y. A Concept Analysis of Oral Anticancer Agent Self-management. Cancer Nurs. 2022;45(2):E374–87.
Prasad V, Massey PR, Fojo T. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol. 2014;32(15):1620–9.
Wang Y, Wang L, Rastegar-Mojarad M, Moon S, Shen F, Afzal N, et al. Clinical information extraction applications: A literature review. J Biomed Inform. 2018;77:34–49.
Jiang Y, Wickersham KE, Zhang X, Barton DL, Farris KB, Krauss JC, et al. Side Effects, Self-Management Activities, and Adherence to Oral Anticancer Agents. Patient Prefer Adherence. 2019;13:2243–52.
Kuhn M, Letunic I, Jensen LJ, Bork P. The SIDER database of drugs and side effects. Nucleic Acids Res. 2016;44(D1):D1075-1079.
U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. NIH. 2017; Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
National Cancer Institute. Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). NIH. 2017; Available from: https://healthcaredelivery.cancer.gov/pro-ctcae/
Flannery MA, Culakova E, Canin BE, Peppone L, Ramsdale E, Mohile SG. Understanding treatment tolerability in older adults with cancer. J Clin Oncol. 2021;39(19):2150–63.
Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006;7(11):903–9.
Fares CM, Williamson TJ, Theisen MK, Cummings A, Bornazyan K, Carroll J, Spiegel ML, Stanton AL, Garon EB. Low concordance of patient-reported outcomes with clinical and clinical trial documentation. JCO Clinical Cancer Inform. 2018;2:1–2.
Chandwani KD, Zhao F, Morrow GR, Deshields TL, Minasian LM, Manola J, Fisch MJ. Lack of patient-clinician concordance in cancer patients: its relation with patient variables. J Pain Symptom Manage. 2017;53(6):988–98.
Basch E, Rogak LJ, Dueck AC. Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther. 2016;38(4):821–30.
Garcia SF, Wortman K, Cella D, Wagner LI, Bass M, Kircher S, Pearman T, Penedo FJ. Implementing electronic health record–integrated screening of patient-reported symptoms and supportive care needs in a comprehensive cancer center. Cancer. 2019;125(22):4059–68.
Hassett MJ, Cronin C, Tsou TC, Wedge J, Bian J, Dizon DS, Hazard-Jenkins H, Osarogiagbon RU, Wong S, Basch E, Austin T. eSyM: An Electronic Health Record-Integrated Patient-Reported Outcomes-Based Cancer Symptom Management Program Used by Six Diverse Health Systems. JCO Clinical Cancer Inform. 2021;6:e2100137.
Bartlett VL, Dhruva SS, Shah ND, Ryan P, Ross JS. Feasibility of using real-world data to replicate clinical trial evidence. JAMA Netw Open. 2019;2(10):e1912869.
Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda®). Eur J Oncol Nurs. 2004;1(8):S31-40.
Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract. 2006;12(3):131–41.
Meulendijks D, van Hasselt JC, Huitema AD, van Tinteren H, Deenen MJ, Beijnen JH, Cats A, Schellens JH. Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. Eur J Cancer. 2016;1(54):120–30.
Karthikeyan G, Jumnani D, Prabhu R, Manoor UK, Supe SS. Prevalence of fatigue among cancer patients receiving various anticancer therapies and its impact on quality of life: a cross-sectional study. Indian J Palliat Care. 2012;18(3):165.
Soones T, Ombres R, Escalante C. An update on cancer-related fatigue in older adults: A narrative review. J Geriatr Oncol. 2021;S1879–4068(21):00169–77.
Poort H, Jacobs JM, Pirl WF, Temel JS, Greer JA. Fatigue in patients on oral targeted or chemotherapy for cancer and associations with anxiety, depression, and quality of life. Palliat Support Care. 2020;18(2):141–7.
Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002;13(4):566–75.
van Beek MWH, Roukens M, Jacobs WCH, Timmer-Bonte JNH, Kramers C. Real-World Adverse Effects of Capecitabine Toxicity in an Elderly Population. Drugs Real World Outcomes. 2018;5(3):161–7.
Kwakman JJM, Elshot YS, Punt CJA, Koopman M. Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev. 2020;14(1):442.
Cataldo JK, Paul S, Cooper B, Skerman H, Alexander K, Aouizerat B, Blackman V, Merriman J, Dunn L, Ritchie C, Yates P. Differences in the symptom experience of older versus younger oncology outpatients: a cross-sectional study. BMC Cancer. 2013;13(1):1–6.
Gijzel SM, Whitson HE, van de Leemput IA, Scheffer M, van Asselt D, Rector JL, OldeRikkert MG, Melis RJ. Resilience in clinical care: getting a grip on the recovery potential of older adults. J Am Geriatr Soc. 2019;67(12):2650–7.
Howard JS, Mattacola CG, Howell DM, Lattermann C. Response shift theory: an application for health-related quality of life in rehabilitation research and practice. J Allied Health. 2011;40(1):31–8.
Vanier A, Oort FJ, McClimans L, Ow N, Gulek BG, Böhnke JR, Sprangers M, Sébille V, Mayo N. Response shift in patient-reported outcomes: definition, theory, and a revised model. Qual Life Res. 2021;30(12):3309–22.
Cho Y, Zhang H, Harris MR, Gong Y, Smith EL, Jiang Y. Acceptance and use of home-based electronic symptom self-reporting systems in patients with cancer: Systematic review. J Med Internet Res. 2021;23(3):e24638.
Jiang Y, Yang G. Enhancing Safety via Medication Self-Management and Timely Reporting. Studies in health technology and informatics. 2021;12(284):463.
Tantoy IY, Cataldo JK, Aouizerat BE, Dhruva A, Miaskowski C. A review of the literature on multiple co-occurring symptoms in patients with colorectal cancer who received chemotherapy alone or chemotherapy with targeted therapies. Cancer Nurs. 2016;39(6):437–45.
Herrstedt J, Lindberg S, Petersen PC. Prevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes. Drugs Aging. 2021;9:1–21.
Rizzo A, Nannini M, Novelli M, Dalia Ricci A, Scioscio VD, Pantaleo MA. Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. Ther Adv Med Oncol. 2020;12:1758835920936932.
Rosati G, Lonardi S, Galli F, Di Bartolomeo M, Ronzoni M, Zampino MG, et al. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. Eur J Cancer. 2021;148:190–201.
Vincent MD, Breadner D, Cripps MC, Jonker DJ, Klimo P, Biagi JJ, et al. Phase I/II trial of dose-reduced capecitabine in elderly patients with advanced colorectal cancer. Curr Oncol. 2017;24(4):e261–8.
Ilich AI, Danilak M, Kim CA, Mulder KE, Spratlin JL, Ghosh S, et al. Effects of gender on capecitabine toxicity in colorectal cancer. J Oncol Pharm Pract. 2016;22(3):454–60.
Feder SL. Data Quality in Electronic Health Records Research: Quality Domains and Assessment Methods. West J Nurs Res. 2018;40(5):753–66.